[go: up one dir, main page]

WO2001051628A3 - Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - Google Patents

Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer Download PDF

Info

Publication number
WO2001051628A3
WO2001051628A3 PCT/US2001/000798 US0100798W WO0151628A3 WO 2001051628 A3 WO2001051628 A3 WO 2001051628A3 US 0100798 W US0100798 W US 0100798W WO 0151628 A3 WO0151628 A3 WO 0151628A3
Authority
WO
WIPO (PCT)
Prior art keywords
kits
methods
breast cancer
assessment
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/000798
Other languages
French (fr)
Other versions
WO2001051628A9 (en
WO2001051628A2 (en
Inventor
James Lillie
Yongyao Xu
Youzhen Wang
Kathleen Steinmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to AU2001229340A priority Critical patent/AU2001229340A1/en
Publication of WO2001051628A2 publication Critical patent/WO2001051628A2/en
Publication of WO2001051628A3 publication Critical patent/WO2001051628A3/en
Anticipated expiration legal-status Critical
Publication of WO2001051628A9 publication Critical patent/WO2001051628A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of novel markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.
PCT/US2001/000798 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer Ceased WO2001051628A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001229340A AU2001229340A1 (en) 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US17607700P 2000-01-14 2000-01-14
US60/176,077 2000-01-14
US18916700P 2000-03-14 2000-03-14
US60/189,167 2000-03-14
US19209900P 2000-03-24 2000-03-24
US60/192,099 2000-03-24
US19348000P 2000-03-29 2000-03-29
US60/193,480 2000-03-29
US20523000P 2000-05-15 2000-05-15
US60/205,230 2000-05-15
US21131500P 2000-06-09 2000-06-09
US60/211,315 2000-06-09
US22053400P 2000-07-25 2000-07-25
US60/220,534 2000-07-25

Publications (3)

Publication Number Publication Date
WO2001051628A2 WO2001051628A2 (en) 2001-07-19
WO2001051628A3 true WO2001051628A3 (en) 2002-04-25
WO2001051628A9 WO2001051628A9 (en) 2003-07-17

Family

ID=27569146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/000798 Ceased WO2001051628A2 (en) 2000-01-14 2001-01-10 Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

Country Status (2)

Country Link
AU (1) AU2001229340A1 (en)
WO (1) WO2001051628A2 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6858204B2 (en) 1999-06-30 2005-02-22 Corxia Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6746846B1 (en) 1999-06-30 2004-06-08 Corixa Corporation Methods for diagnosing lung cancer
US20030211510A1 (en) 1999-06-30 2003-11-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030125245A1 (en) 1999-06-30 2003-07-03 Tongtong Wang Compositions and methods for therapy and diagnosis of lung cancer
EP1892249A1 (en) * 1999-09-01 2008-02-27 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
ES2304126T3 (en) 2000-01-26 2008-09-16 Agensys, Inc. 84P2A9: A SPECIFIC PROTEIN OF PROSTATE AND TESTICLES HIGHLY EXPRESSED IN CANCER DE PROSTATA.
PT1276867E (en) * 2000-03-22 2006-12-29 Bayer Healthcare Ag Use of human latrophilin-like g protein-coupled receptor in screening methods
WO2002006326A2 (en) * 2000-07-14 2002-01-24 Millennium Pharmaceuticals, Inc. 62088, a human nucleoside phosphatase family member and uses thereof
US7358353B2 (en) 2000-08-22 2008-04-15 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
WO2002016593A2 (en) 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
EP1320587A2 (en) * 2000-08-24 2003-06-25 Millenium Pharmaceuticals, Inc. 46863, a human methyltransferase and uses thereof
WO2002026955A2 (en) * 2000-09-29 2002-04-04 Lexicon Genetics Incorporated Human proteases and polynucleotides encoding the same
DE60140559D1 (en) * 2000-10-05 2009-12-31 Millenium Pharmaceuticals Inc 32144, A HUMAN FATTY ACID HYDROLASE AND ITS USES
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20040003418A1 (en) 2001-04-10 2004-01-01 Aya Jakobovits Nucleic acid and corresponding protein entitled 158P3D2 useful in treatment and detection of cancer
EP2280030A3 (en) 2001-04-10 2011-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1385962A2 (en) * 2001-05-02 2004-02-04 Bayer HealthCare AG Human prolyl 4-hydroxylases
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
DK1410011T3 (en) 2001-06-18 2011-07-18 Netherlands Cancer Inst Diagnosis and prognosis of breast cancer patients
JP2003250550A (en) * 2002-02-25 2003-09-09 Nissui Pharm Co Ltd Fat cell differentiation-related gene and protein
DE10211088A1 (en) * 2002-03-13 2003-09-25 Ugur Sahin Gene products differentially expressed in tumors and their use
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2003255459A1 (en) * 2002-08-19 2004-03-11 Bayer Healthcare Ag Regulation of human secretin-type gpcr (latrophilin)
TW200413539A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Genes and polypeptides relating to prostate cancers
JP4643450B2 (en) 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス Cancer high expression gene
ES2303390B1 (en) * 2003-09-24 2009-08-17 Progenika Biopharma, S.A. METHODS FOR IN VITRO AND IN VITRO DIAGNOSIS OF THE DUCTAL PANCREAS ADENOCARCINOMA AND / OR OF A PANCREATITIS; AND FOR THE DEVELOPMENT OF PHARMACS AGAINST DUCTAL PANCREAS ADENOCARCINOMA AND / OR AGAINST A PANCREATITIS.
US7807176B2 (en) 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
US20090022708A1 (en) * 2004-12-22 2009-01-22 Lobie Peter E Trefoil Factors and Methods of Treating Proliferation Disorders Using Same
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
FR2892730A1 (en) * 2005-10-28 2007-05-04 Biomerieux Sa Detecting the presence/risk of cancer development in a mammal, comprises detecting the presence/absence or (relative) quantity e.g. of nucleic acids and/or polypeptides coded by the nucleic acids, which indicates the presence/risk
JP2007267692A (en) * 2006-03-31 2007-10-18 Sysmex Corp Metastasis marker for lymph node and primer for breast cancer and method for judging lymph node metastasis of breast cancer using the same marker
JP6083871B2 (en) 2010-09-29 2017-02-22 アジェンシス，インコーポレイテッド Antibody drug conjugate (ADC) that binds to 191P4D12 protein
WO2013191950A2 (en) 2012-06-22 2013-12-27 Monsanto Technology Llc Unique modular vector design
DK2887959T3 (en) 2012-08-23 2019-02-18 Agensys Inc ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 158P1D7 PROTEINS
CA3121573A1 (en) 2018-12-03 2020-06-11 Agensys, Inc. Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROWN M A ET AL: "PHYSICAL MAPPING, CLONING, AND IDENTIFICATION OF GENES WITHIN A 500-KB REGION CONTAINING BRCA1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 92, 1 May 1995 (1995-05-01), pages 4362 - 4366, XP002017873, ISSN: 0027-8424 *
DATABASE EMBL 11 May 1999 (1999-05-11), MARRA M ET AL: "uk22d10.y1 Sugano mouse embryo mewa Mus musculus cDNA clone", XP002175764 *
DATABASE EMBL 28 October 1999 (1999-10-28), BIRREN B ET AL: "Homo sapiens clone RP11-2L5", XP002175765 *
JI H ET AL: "IDENTIFICATION OF A BREAST CANCER-SPECIFIC GENE, BCSG1, BY DIRECT DIFFERENTIAL CDNA SEQUENCING", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 4, 15 February 1997 (1997-02-15), pages 759 - 764, XP002065403, ISSN: 0008-5472 *
WOOSTER R ET AL: "IDENTIFICATION OF THE BREAST CANCER SUSCEPTIBILITY GENE BRCA2", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 378, 1 December 1995 (1995-12-01), pages 789 - 792, XP002029512, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
AU2001229340A1 (en) 2001-07-24
WO2001051628A9 (en) 2003-07-17
WO2001051628A2 (en) 2001-07-19

Similar Documents

Publication Publication Date Title
WO2001051628A3 (en) Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2001053836A3 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2001070979A3 (en) Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer
WO2001042467A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2001060860A3 (en) Genes differentially expressed in human prostate cancer and their use
WO2001086002A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of psoriasis
AU2002337657A1 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2001018542A3 (en) Identification, assessment, prevention, and therapy of ovarian cancer
WO2003000012A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
WO2003060465A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2005032328A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2007095186A8 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2004061423A3 (en) Compositions and methods for diagnosing and treating colon cancers
WO2001046697A3 (en) Identification, assessment, prevention, and therapy of breast cancer
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2002044418A3 (en) Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
WO2002085298A3 (en) Method for detecting breast cancer cells
WO2005034732A3 (en) Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2002046765A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2005118869A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
WO2001042792A3 (en) Diagnosis of cervical cancer using marker proteins
WO2002044360A3 (en) Modified arginine deiminase
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: TABLES 3 AND 4, SEQUENCE LISTING REPLACED BY CORRECT TABLES 3 AND 4; DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

NENP Non-entry into the national phase

Ref country code: JP